MPM Capital and Qiming Venture Partners USA have co-led a series A round for Umoja Biopharma, based on research at Purdue University and Seattle Children’s Research Institute.

Umoja Biopharma, a US-based in-vivo immunotherapy platform developer exploiting research from Purdue University and Seattle Children’s Research Institute, launched with a $53m series A round on Wednesday co-led by MPM Capital and Qiming Venture Partners USA.
Founded in early 2019, Umoja is working on an integrated in-vivo immunotherapy platform targeting blood cancers and solid tumours, aiming to deliver its treatments with a simplicity and cost efficiency that enable widespread use.
Umoja advances work led by Philip Low, the…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in